Esperion Therapeutics Inc (ESPR)
EBITDA Growth
-114.15%
Quarterly · Period ending:
ESPR EBITDA Growth
Year-over-year change vs the same period a year earlier
Latest reported-114.15%period ending
Latest reported-114.15%period ending
ESPR Quarterly EBITDA YoY % (-42.50% → -114.15%)
Year-over-year change
High-resolution chart · PNG
ESPR ebitda growth history
Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | EBITDA Growth |
|---|---|
| -114.149% | |
| 1,873.1362% | |
| 35.7936% | |
| 116.1604% | |
| -127.8182% | |
| 88.2052% | |
| 45.0379% | |
| -36.3397% | |
| 259.749% | |
| -0.5235% | |
| 35.8061% | |
| 31.9045% | |
| -11.137% | |
| 20.3159% | |
| 26.4848% | |
| -60.3534% | |
| 48.5633% | |
| 45.9705% | |
| 30.8254% | |
| -125.0222% | |
| -11.7409% | |
| -65.2518% | |
| -24.9763% | |
| 338.838% | |
| -185.0253% | |
| 3.7422% | |
| -28.9804% | |
| -16.6943% | |
| 285.7664% | |
| -58.6502% | |
| -9.1275% | |
| -6.4732% | |
| -14.7305% | |
| -31.1667% | |
| -164.7826% | |
| -214.2435% | |
| -183.2558% | |
| -118.8502% | |
| -36.7203% | |
| -13.6758% | |
| -26.7904% | |
| -41.2162% | |
| -30.7597% | |
| -32.465% | |
| -44.2752% | |
| 4.1234% | |
| -78.8176% | |
| -116.5217% | |
| -136.1003% | |
| -345.8659% | |
| -82.6117% | |
| -50.4654% | |
| -55.0762% | |
| 14.039% | |
| -7.2132% | |
| 3.551% | |
| 1.0222% | |
| -14.9277% | |
| 4.6836% | |
| 8.3541% | |
| -24.2262% | |
| 18.8112% | |
| -1.3889% | |
| -42.5038% |